A5055702421- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Treatment of Major Depression
- Health Systems, Economic Evaluations, Quality of Life
- Functional Brain Connectivity Studies
- Cholinesterase and Neurodegenerative Diseases
- Multisensory perception and integration
- Olfactory and Sensory Function Studies
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Coastal and Marine Management
- Health, Environment, Cognitive Aging
- Neuroscience and Neuropharmacology Research
- Coordination Chemistry and Organometallics
- Intensive Care Unit Cognitive Disorders
- Tryptophan and brain disorders
- Memory and Neural Mechanisms
- Blood Pressure and Hypertension Studies
- Neurological Disease Mechanisms and Treatments
- Cancer-related cognitive impairment studies
- Neurobiology of Language and Bilingualism
- Attention Deficit Hyperactivity Disorder
- Neurological Disorders and Treatments
- Environmental Conservation and Management
- American Environmental and Regional History
- Nitric Oxide and Endothelin Effects
King's College London
2007-2025
Amsterdam University Medical Centers
2019-2024
Vrije Universiteit Amsterdam
2019-2024
Cambridge Cognition (United Kingdom)
2015-2024
Amsterdam Neuroscience
2016-2024
National Brain Research Centre
2023
Amsterdam UMC Location Vrije Universiteit Amsterdam
2015-2023
Princess Alexandra Hospital
2022
Neurotrack Technologies (United States)
2021
Brain (Germany)
2021
Two methods were utilized to demonstrate the peroxidation of chloride ion a free species (HOCl or Cl2) by myeloperoxidase. The peroxidase caused volatilization radioactivity from soultions containing hydrogen peroxide and [36Cl]NaCl, catalyzed formation HOCl when solutions contianing these components passed through Millipore filter which was adsorbed. In this flow system, 90 mug canine myeloperoxidase generated 80 muM in presence 200 H2O2 at rate corresponding turnover 100 min-1. Under...
PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD). A recent Phase IIa double-blind, randomized, placebo-controlled trial found the 250 mg dose was well-tolerated, significantly lowered cerebrospinal fluid (CSF) levels amyloid-beta42, and improved executive function on Neuro-psychological Test Battery (NTB) within 12 weeks treatment patients with AD. In post-hoc analysis reported here, cognitive, blood marker, CSF neurochemistry...
Souvenaid aims to improve synapse formation and function. An earlier study in patients with Alzheimer's disease (AD) showed that increased memory performance after 12 weeks drug-naïve mild AD. The Souvenir II was a 24
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity cerebral glucose uptake, increasing the proliferation neuronal progenitor cells. The primary objective study to evaluate change metabolic rate after 12 months treatment with participants compared those...
Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not widely or systematically studied. Aim: The aim this study was explore the safety simultaneous administration psilocybin healthy participants in largest randomised controlled trial date. Primary and secondary endpoints assessed short- longer-term change functioning, as by Cambridge...
Synaesthesia is a condition in which mixing of the senses occurs; for example, sounds trigger experience colour. Previous reports suggest this may be familial, but no systematic studies exist. In addition, there are reliable prevalence or sex-ratio figures condition, essential establishing if reported sex ratio (female bias) reliable, and implicates sex-linked genetic mechanism. Two independent population were conducted city Cambridge, England (studies 1 2 here), as necessary background to...
Evidence was reported earlier from a single case that chromatic-lexical (CL) synaesthesia genuine phenomenon. A study is presented in which nine subjects were tested who also having coloured hearing. The following questions addressed: (a) these cases (ie consistent over time), (b) they truly lexical, or rather variants of this condition, such as chromatic-graphemic (CG) chromatic-phonemic (CP) synaesthesia, (c) did the experimental show any commonalities between them, and (d) able to give...
In a small proportion of the normal population, stimulation in one modality can lead to perceptual experience another, phenomenon known as synaesthesia. most common form synaesthesia, hearing word result colour. We have used technique PET, which detects brain activity changes regional cerebral blood flow (rCBF), study physiology colour-word synaesthesia group six synaesthete women. During rCBF measurements synaesthetes and controls were blindfolded presented with spoken words or pure tones....
Tests of verbal fluency, whether Semantic Fluency (SF) or Phonological (PF), are often used as a standard method neuropsychological assessment. However, very little normative data, standardized on UK sample, is available, and known about the utility popularly 'short‐forms these tasks. Additionally, fluency test‐retest reliability. In this report we describe performance N = 365 normal participants version SF requiring generation exemplars category 'animals PF task to generate words beginning...
Objective: To report the psychometric properties of an alternative instrument to cognitive subscale Alzheimer's Disease Assessment Scale, a neuropsychological test battery (NTB) for measuring drug efficacy in Alzheimer disease clinical trials. Design:The NTB was evaluated randomized, doubleblind, placebo-controlled trial AN1792(QS-21) (synthetic -amyloid plus adjuvant) (300 patients) and isotonic sodium chloride solution (72 patients).The testretest reliability examined, correlated with...
Management of cognitive deficits in Major Depressive Disorder (MDD) remains an important unmet need. This meta-analysis evaluated the effects vortioxetine on cognition patients with MDD.Random was applied to three randomized, double-blind, placebo-controlled 8-week trials (5-20mg/day) MDD, and separately two duloxetine-referenced trials. The primary outcome measure change Digit Symbol Substitution Test (DSST) score. Standardized effect sizes (SES) versus placebo (Cohen's d ) were used as...
To validate the THINC-integrated tool (THINC-it)-a freely available, patient-administered, computerized screening integrating subjective and objective measures of cognitive function in adults with major depressive disorder (MDD).Subjects aged 18 to 65 years (n = 100) recurrent MDD experiencing a episode at least moderate severity were evaluated compared age-, sex-, education-matched healthy controls 100). Between January June 2016, subjects completed THINC-it, which includes variants Choice...
PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in formation synaptotoxic pyroglutamate-A-beta oligomers. We report on first clinical study with subjects biomarker-proven Alzheimer's disease (AD). The aim was to determine maximal tolerated dose, target occupancy and treatment-related pharmacodynamic effects. exploratory efficacy readouts selected were tailored patient population early AD. therapeutic approach focuses synaptic dysfunction as captured by...
Abstract The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large‐scale proof‐of‐concept trials in predementia disease (AD). Within EPAD, the monitoring cognitive trajectories preclinical period constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved most measures have been developed for around dementia diagnosis. EPAD Scientific Advisory Group Clinical and Cognitive Outcomes...
Abstract Background In preclinical studies, p38⍺ kinase is implicated in Alzheimer’s disease (AD) pathogenesis. animal models, it mediates impaired synaptic dysfunction the hippocampus, causing memory deficits, and involved amyloid-beta (Aβ) production tau pathology. Methods The REVERSE-SD (synaptic dysfunction) study was a multi-center phase 2, randomized, double-blind, placebo-controlled trial of inhibitor neflamapimod; conducted December 29, 2017, to June 17, 2019; 464 participants...
Abstract A crucial aspect of any clinical trial is using the right outcome measure to assess treatment efficacy. Compared rapidly evolved understanding and measurement pathophysiology in preclinical early symptomatic stages Alzheimer's disease (AD), relatively less progress has been made evolution assessments (COAs) for those stages. The current paper aims provide a benchmark design evaluation COAs use AD trials. We discuss lessons learned on capturing cognitive changes predementia AD,...